HOME
The Info List - ViiV Healthcare


--- Advertisement ---



ViiV Healthcare (/viːv/ VEEV) is a pharmaceutical company specialising in the development of therapies for HIV infection that was created as a joint venture by Pfizer
Pfizer
and GlaxoSmithKline
GlaxoSmithKline
in November 2009 with both companies transferring their HIV assets to the new company.[1] In 2012 Shionogi
Shionogi
joined the company. 76.5% of the company is now owned by GlaxoSmithKline, 13.5% by Pfizer
Pfizer
and 10% by Shionogi.[2] This ownership structure may change depending upon the achievement of certain milestones.[1] ViiV Healthcare's products have a market share of approximately 19%[3] of the global HIV market, which makes it the second largest healthcare company, following after Gilead Sciences, that is working on the treatment of HIV.[4] ViiV Healthcare's headquarters are in Brentford
Brentford
in the United Kingdom and it has sites in a number of other countries including; the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[5]

Contents

1 Products 2 Treatment access programs 3 See also 4 References

Products[edit] The company currently markets 12 products:[6][7]

Nucleoside reverse transcriptase inhibitors (NRTIs):

abacavir (brand name Ziagen) lamivudine (brand names Epivir and 3TC) zidovudine (brand name Retrovir and AZT)

Non-nucleoside reverse transcriptase inhibitors (NNRTIs):

delavirdine (brand name Rescriptor)

Integrase strand transfer inhibitors (INSTIs):

dolutegravir (brand name Tivicay)

Protease inhibitors:

fosamprenavir (brand names Lexiva and Telzir) nelfinavir (brand name Viracept)

Entry inhibitors:

maraviroc (brand names Selzentry and Celsentri)

Antiretroviral fixed-dose combinations, including two single-pill regimens:

abacavir/lamivudine (brand names Epzicom and Kivexa) abacavir/lamivudine/zidovudine (brand name Trizivir) lamivudine/zidovudine (brand name Combivir) abacavir/dolutegravir/lamivudine (brand name Triumeq)

Treatment access programs[edit] ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer
Pfizer
and GlaxoSmithKline
GlaxoSmithKline
had been involved in prior to the setting up of the company. This program covers all low and middle income countries, as well as all of Sub-Saharan Africa.[8] The company has also granted voluntary licenses to 14 generics companies to enable the low-cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.[8][9] See also[edit]

Pharmaceutical
Pharmaceutical
industry in the United Kingdom

References[edit]

^ a b Jacks, Andrew "GSK and Pfizer
Pfizer
to Merge HIV Portfolios Financial Times. 16 April 2010 (subscription required) ^ " Shionogi
Shionogi
and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio". viivhealthcare.com. Retrieved 7 March 2014.  ^ " ViiV Healthcare Company Website. About Us — At a Glance" Archived 9 December 2010 at the Wayback Machine. Accessed 13 October 2010 ^ Jacks, Andrew "ViiV Vows Joint Venture Will Help Fight HIV" Financial Times. 3 November 2009 (subscription required) ^ " ViiV Healthcare Company Website. About Us — Locations" Archived 9 December 2010 at the Wayback Machine. Accessed 13 October 2010 ^ ViiV Healthcare Company Website. Our Medicines. Archived 28 February 2017 at the Wayback Machine. Accessed 21 July 2017 ^ McNeil, Donald "AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease" New York Times. 9 November 2009 ^ a b " ViiV Healthcare Company Website. We Improve Access to Our Medicines" Accessed 12 January 2014 ^ Reuters "Glaxo, Pfizer
Pfizer
JV Opens HIV Pipeline to Generic Companies" Africa — the Good News. 19 July 2010

v t e

GlaxoSmithKline

Subsidiaries

GlaxoSmithKline
GlaxoSmithKline
Pakistan GlaxoSmithKline
GlaxoSmithKline
Pharmaceuticals Ltd Stiefel Laboratories ViiV Healthcare (85%)

Predecessors, acquisitions

Allen & Hanburys Beecham Group Block Drug Burroughs Wellcome Glaxo Glaxo Wellcome Human Genome Sciences Recherche et Industrie Thérapeutiques Reliant Pharmaceuticals S. E. Massengill Company SmithKline Beecham Smith, Kline & French

Products

Current

Pharmaceuticals

Advair Alli Augmentin Avandia Beconase Boniva Flixonase Hycamtin Lamictal Paxil/Seroxat Serlipet Tagamet Ventolin Wellbutrin/Zyban Zantac … more

Vaccines

Hepatyrix Pandemrix Twinrix

Other

Aquafresh Horlicks Nicoderm Nicorette NiQuitin Sensodyne Tums
Tums
… more

Former

BC Powder Geritol Goody's Powder Lucozade Ribena

People

Board of Directors

Philip Hampton Emma Walmsley Simon Dingemans Roy M. Anderson Manvinder Banga Patrick Vallance Vivienne Cox Lynn Elsenhans Jesse Goodman Judy Lewent Urs Rohner Laurie Glimcher

Other

Thomas Beecham Silas M. Burroughs Mahlon Kline John K. Smith Henry Wellcome Andrew Witty Chris Gent

Litigation

Canada v. GlaxoSmithKline
GlaxoSmithKline
Inc. Christopher v. SmithKline Beecham Corp. GlaxoSmithKline
GlaxoSmithKline
Services Unlimited v Commission United States v. Glaxo Group Ltd. United States v. GlaxoSmithKline

Other

Drug Industry Document Archive GlaxoSmithKline
GlaxoSmithKline
Prize Side Effects Study 329

Category

v t e

Pharmaceutical
Pharmaceutical
and biotechnology industry in the United Kingdom

Manufacturing in the United Kingdom Economy of the United Kingdom

companies

current

AAH Pharmaceuticals Alliance Boots Astex AstraZeneca
AstraZeneca
(MedImmune) BTG Cyclacel Dechra Pharmaceuticals GE Healthcare Genus GlaxoSmithKline Hikma Pharmaceuticals Indivior MacFarlan Smith Norbrook Group Oxford BioMedica Pfizer
Pfizer
UK Phytopharm Proximagen Shire Silence Therapeutics TBS GB Unipath Vectura Group Vernalis ViiV Healthcare

defunct

Allen & Hanburys Amersham Beecham Group Cambridge Antibody Technology Celltech Chiroscience Distillers Company Fisons Glaxo Wellcome ICI Reliant Pharmaceuticals Renovo Zeneca

government and regulatory bodies

Commission on Human Medicines Department of Health European Directorate for the Quality of Medicines European Medicines Agency Medicines and Healthcare Products Regulatory Agency National Collaborating Centre for Mental Health National Patient Safety Agency Pharmaceutical
Pharmaceutical
Price Regulation Scheme Pharmaceutical
Pharmaceutical
Society of Northern Ireland General Pharmaceutical
Pharmaceutical
Council Scottish Medicines Consortium Veterinary Medicines Directorate

industry and professional bodies

Association of the British Pharmaceutical
Pharmaceutical
Industry Chemical Industries Association European Federation of Biotechnology European Federation of Pharmaceutical
Pharmaceutical
Industries and Associations Faculty of Pharmaceutical
Pharmaceutical
Medicine Pharmacists' Defence Association Royal Pharmaceutical
Pharmaceutical
Society of Great Britain Worshipful Society of Apothecaries

books and journals

Bandolier Bad Pharma
Bad Pharma
(2012) British National Formulary British National Formulary
British National Formulary
for Children Monthly Index of Medical Specialities Side Effects (2008) The Pharmaceutical
Pharmaceutical
Journal

other

British Approved Name British Pharmacopoeia DrugScope European and Developing Countries Clinical Trials Partnership European Pharmacopoeia List of world's largest pharmaceutical companies Pharmaceutical
Pharmaceutical
Services Negotiating Committee Wellcome Tru

.